The Anti-SARS-CoV-2 Monoclonal Antibody, Bamlanivimab, Minimally Impacts the Endogenous Immune Response to COVID-19 Vaccination

Researchers evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study.